Splenectomy in agnogenic myeloid metaplasia.
暂无分享,去创建一个
[1] S Quaglini,et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. , 1998, Blood.
[2] P. Morel,et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.
[3] A. Tefferi,et al. Agnogenic myeloid metaplasia. , 1995, Seminars in oncology.
[4] P. Rameshwar,et al. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta. , 1994, Journal of immunology.
[5] A. Tichelli,et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. , 1993, The New England journal of medicine.
[6] P. Gobbi,et al. Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Thiele,et al. Splenic Megakaryocytopoiesis in Primary (Idiopathic) Osteomyelofibrosis , 1992 .
[8] V. Praloran,et al. Increased circulating CSF-1 (M-CSF) in myeloproliferative disease: association with myeloid metaplasia and peripheral bone marrow extension. , 1989, Blood.
[9] W. Remine,et al. Splenectomy in myeloid metaplasia. , 1979, Blood.